3-溴丙酮酸肿瘤多药耐药逆转剂的研究进展
作者：吴弄;邓媛媛;徐俊;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2013,28(04):-421-424
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：3-溴丙酮酸;肿瘤;糖酵解;多药耐药
Key words：
基金项目：
中文摘要
鉴于肿瘤细胞对糖酵解的高度依赖性及多药耐药相关ABC蛋白存在依赖ATP供能的共性,选择以糖酵解途径为靶标的3-溴丙酮酸研究肿瘤MDR逆转剂是有效克服肿瘤MDR的新思路。但3-溴丙酮酸的稳定性、靶向性及其毒理部分的研究尚未取得突破性的进展,现对3-溴丙酮酸的研究进展作一综述。
参考文献
[1]Leonard GD,Fojo T,Bates SE.The role of ABC transporters in clinical practice[J].Oncologist,2003,8(5):411-424.
[2]Thomas H,Coley HM.Overcoming multidrug resistance in canc-er:An update on the clinical strategy of inhibiting p-glycoprotein[J].Can Contr,2003,10(2):159-165.
[3]Borowski E,Bontemps-Gracz MM,Piwkowska A.Strategies for overcoming ABC-transporters-mediated multidrug resistance(MDR)of tumor cells[J].Acta Biochim Pol,2005,52(3):609-627.
[4]Pusztai L,Wagner P,Ibrahim N,et al.Phase II study of tariqui-dar,a selective Pglycoprotein inhibitor,in patients with chemo-therapy-resistant,advanced breast carcinoma[J].Can,2005,104(4):682-691.
[5]Warburn O,Dickens F.The metabolism of tumors[J].Am J Med Sci,1931,182(1):123.
[6]Raghunand N,Gatenby R,Gillies R.Microenvironmental and cel-lular consequences of altered blood flow in tumours[J].British J Radi,2003,76(1):11-22.
[7]Upadhyay M,Samal J,Kandpal M,et al.The Warburg effect:In-sights from the past decade[J].Pharmaco&Ther,2012,in-press.
[8]Martinez-Zaguilan R,Seftor EA,Seftor REB,et al.Acidic pH enhances the invasive behavior of human melanoma cells[J].Clin Experimental Metastasis,1996,14(2):176-186.
[9]De Milito A,Fais S.Tumor acidity,chemoresistance and proton pump inhibitors[J].Future Oncol,2005,1(6):779-786.
[10]Vander Heiden MG,Cantley LC,Thompson CB.Understanding the Warburg effect:the metabolic requirements of cell prolifera-tion[J].Sci Sign,2009,324(5930):1029-1033.
[11]Ihrlund LS,Hernlund E,Khan O,et al.3-Bromopyruvate as in-hibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs[J].Mol Oncol,2008,2(1):94-101.
[12]Nakano A,Tsuji D,Miki H,et al.Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells[J].Plos One,2011,6(11):e27222.
[13]Nakano A,Miki H,Nakamura S,et al.Up-regulation of hexoki-naseII in myeloma cells:targeting myeloma cells with3-bro-mopyruvate[J].J Bioenerg Biomembr,2012,44(1):31-38.
[14]Pedersen PL,Mathupala S,Rempel A,et al.Mitochondrial bound type II hexokinase:a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention[J].Biochim et Biophys Acta(BBA)-Bioenerg,2002,1555(1):14-20.
[15]Ko YH,Pedersen PL,Geschwind J.Glucose catabolism in the rab-bit VX2tumor model for liver cancer:characterization and targe-ting hexokinase[J].Can Lett,2001,173(1):83-91.
[16]Mathupala S,Ko Y,Pedersen P.HexokinaseⅡ:cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria[J].Oncogene,2006,25(34):4777-4786.
[17]Mathupala SP,Ko YH,Pedersen PL.Hexokinase-2bound to mitochondria:cancer's stygian link to the“Warburg Effect”and a pivotal target for effective therapy[J].Seminars Cancerbiology,2009,19(1):17-24.
[18]Pathania D,Millard M,Neamati N.Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism[J].Advanced drug delivery reviews,2009,61(14):1250-1275.
[19]Chen Z,Zhang H,Lu W,et al.Role of mitochondria-associated hexokinaseⅡin cancer cell death induced by3-bromopyruvate[J].Biochimica et Biophysica Acta(BBA)-Bioenergetics,2009,1787(5):553-560.
[20]Majewski N,Nogueira V,Bhaskar P,et al.Hexokinase-mitochon-dria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak[J].Molecular cell,2004,16(5):819-830.
[21]Tristan C,Shahani N,Sedlak TW,et al.The diverse functions of GAPDH:views from different subcellular compartments[J].Cel-lular Signalling,2011,23(2):317-323.
[22]Pereira DSA,El-Bacha T,Kyaw N,et al.Inhibition of energy-producing pathways of HepG2cells by3-bromopyruvate1[J].Biochem J,2009,417:717-726.
[23]Dell'Antone P.Targets of3-bromopyruvate,a new,energy de-pleting,anticancer agent[J].Med Chem,2009,5(6):491-496.
[24]Ganapathy-Kanniappan S,Geschwind JFH,Kunjithapatham R,et al.Glyceraldehyde-3-phosphate dehydrogenase(GAPDH)is pyruvylated during3-bromopyruvate mediated cancer cell death[J].Antican Res,2009,29(12):4909-4918.
[25]Ralph SJ,Rodríguez-Enríquez S,Neuzil J,et al.Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger[J].Mol Asp Med,2010,31(1):29-59.
[26]Qin JZ,Xin H,Nickoloff B.3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines[J].Biochem Biophys Res Comm,2010,396(2):495-500.
[27]Cardaci S,Rizza S,Filomeni G,et al.Glutamine Deprivation En-hances Antitumor Activity of3-Bromopyruvate through the Sta-bilization of Monocarboxylate Transporter-1[J].Canc Res,2012,72(17):4526-4536.
[28]Geschwind JF,Georgiades CS,Ko YH,et al.Recently elucidated energy catabolism pathways provide opportunities for novel treat-ments in hepatocellular carcinoma[J].Exp Rev Anticanc Ther,2004,4(3):449-457.
[29]Ko YH,Smith BL,Wang Y,et al.Advanced cancers:Eradication in all cases using3-bromopyruvate therapy to deplete ATP[J].Biochem Biophys Res Comm,2004,324(1):269-275.
[30]Philippe I,Xiao-Dong Z,Edwige L,et al.Experimental results u-sing3-bromopyruvate in mesothelioma:In vitro and in vivo stud-ies[J].J Bioenerg Biomemb,2012,44(1):81-90.
[31]Schaefer NG,Geschwind JF,Engles J,et al.Systemic administra-tion of3-bromopyruvate in treating disseminated aggressive lym-phoma[J].Trans Res,2012,159(1):51-57.
[32]Ko YH,Geschwind JF,Pedersen PL.Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP produc-tion[P].2012,Patent No:US8,119,116B2,Date of patent:Feb.21,2012.
[33]Berndtsson M,Hgg M,Panaretakis T,et al.Acute apoptosis by cis-platin requires induction of reactive oxygen species but is not as-sociated with damage to nuclear DNA[J].Int J Can,2007,120(1):175-180.
[34]Lfstedt L,Johansson J,Pedersen AB,et al.Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to3-bromopyruvate[J].Can Bio&Ther,2012,13(14):1454-1462.
[35]Cao X,Jia G,Zhang T,et al.Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90inhibitor and glycolysis inhibitor in RIP1-Tag2transgenic pancreatic tumor model[J].Can Chemother Pharmaco,2008,62(6):985-994.
[36]Xu R,Pelicano H,Zhou Y,et al.Inhibition of glycolysis in canc-er cells:A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia[J].Can Res,2005,65(2):613-621.
[37]Vali M,Vossen JA,Buijs M,et al.Targeting of VX2rabbit liver tumor by selective delivery of3-bromopyruvate:A biodistribution and survival study[J].J Pharmaco Exper Ther,2008,327(1):32-37.
[38]Chang JM,Chung JW,Jae HJ,et al.Local toxicity of hepatic arte-rial infusion of hexokinase II inhibitor,3-bromopyruvate:In vivo investigation in normal rabbit model[J].Acad Radi,2007,14(1):85-92.
【关闭】
